MiniMed Group, Inc.

MiniMed Group, Inc. (MMED) priced its initial public offering on Mar 6, 2026 at $20.00 per share, raising $560M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $5.62B. Goldman Sachs was lead-left underwriter, joined by BofA Securities, Citigroup and Morgan Stanley and others. Cleary Gottlieb advised the company and Davis Polk advised the underwriters.

MiniMed Group, Inc. is a global medical technology company that develops, manufactures and markets solutions for diabetes management. It commercializes all parts of an integrated diabetes management system and has operated for more than 40 years.

Status

IPO

Ticker

MMED

Exchange

Nasdaq Global Select

Priced

Mar 6, 2026

IPO price

$20.00

Raised

$560M

Market cap at IPO price

$5.62B

First filed

Dec 19, 2025

Underwriters

Goldman Sachs, BofA Securities, Citigroup, Morgan Stanley, Barclays, Deutsche Bank, Mizuho, Wells Fargo, Evercore ISI, Piper Sandler, BTIG and William Blair

Company counsel

Cleary Gottlieb

Underwriters' counsel

Davis Polk

Sector

Healthcare

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.